Can I Take Creatine with Crestor (Rosuvastatin)?

Why This Question Comes Up So Often

Rosuvastatin is one of the most prescribed medications in the United States, with over 40 million prescriptions dispensed annually. Creatine monohydrate, meanwhile, is among the most popular dietary supplements in resistance-training populations. The overlap between statin users who also exercise and supplement with creatine is substantial, and many patients worry that combining the two could harm their kidneys or mask a dangerous side effect.

The Lab Value That Causes Confusion

The concern centers on one lab value: serum creatinine. Rosuvastatin's FDA-approved labeling recommends monitoring renal function during therapy, particularly at the 40 mg dose, because post-marketing reports have linked high-dose rosuvastatin to proteinuria and hematuria [1]. Creatine supplementation, through a completely separate mechanism, raises serum creatinine by approximately 20-30% because creatinine is a direct metabolic byproduct of creatine [2]. When both factors converge on the same lab panel, a clinician who does not know about the creatine use may misinterpret the elevated creatinine as statin-induced kidney injury.

Why Prescribers React

That misinterpretation can lead to unnecessary dose reductions, drug discontinuation, or invasive follow-up testing. A 2019 review in the Journal of the International Society of Sports Nutrition confirmed that creatine supplementation in healthy individuals does not impair renal function despite raising creatinine concentrations [3]. The distinction between a benign lab artifact and actual nephrotoxicity matters enormously for patients who benefit from statin therapy.

How Rosuvastatin Works (and Where Kidneys Enter the Picture)

Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. It is the most potent commercially available statin, capable of reducing LDL-C by 52-63% at the 40 mg dose according to the STELLAR trial (N=2,431) [4].

Renal Elimination Pathway

Unlike atorvastatin and simvastatin, which undergo extensive hepatic CYP3A4 metabolism, rosuvastatin is primarily eliminated unchanged. Approximately 28% of the oral dose is recovered in urine, and 72% in feces [1]. This renal excretion component is why the FDA label specifically warns about kidney monitoring at higher doses. Patients with an eGFR <30 mL/min/1.73 m² should not receive rosuvastatin at doses above 10 mg [1].

The 40 mg Dose Concern

Post-marketing surveillance identified cases of proteinuria in patients taking rosuvastatin 40 mg. The JUPITER trial (N=17,802), which studied rosuvastatin 20 mg versus placebo in primary prevention, did not find a significant increase in renal adverse events at that dose [5]. The kidney concern is largely confined to the 40 mg tier, which is rarely prescribed as a starting dose.

How Creatine Affects Lab Results

Creatine monohydrate is stored in skeletal muscle as phosphocreatine and serves as a rapid-turnover energy buffer during high-intensity exercise. A standard loading dose of 20 g/day for 5-7 days followed by 3-5 g/day maintenance saturates intramuscular creatine stores.

The Creatinine Production Chain

Creatine undergoes non-enzymatic dehydration in muscle tissue to form creatinine, which enters the bloodstream and is filtered by the kidneys. More creatine in the body means more creatinine produced daily. This is a stoichiometric relationship, not a sign of renal damage. A meta-analysis of 15 controlled trials (N=575) published in the European Journal of Clinical Nutrition found no evidence that creatine supplementation at recommended doses impairs glomerular filtration rate in healthy adults [6].

What the Numbers Actually Look Like

A healthy male with a baseline serum creatinine of 1.0 mg/dL may see values rise to 1.2-1.3 mg/dL after creatine loading. That single data point, without context, crosses the upper limit of the reference range (typically 1.2 mg/dL) and drops the calculated eGFR by 10-15 mL/min/1.73 m². A physician monitoring statin therapy who sees that shift will reasonably suspect a drug-related adverse effect.

Is There a True Drug-Supplement Interaction?

No. There is no documented pharmacokinetic or pharmacodynamic interaction between rosuvastatin and creatine monohydrate.

Pharmacokinetic Analysis

Rosuvastatin is a substrate of OATP1B1 and BCRP transporters. It has minimal CYP450 metabolism. Creatine is a small amino acid derivative that does not bind plasma proteins, does not undergo hepatic metabolism, and does not interact with drug transporter proteins [7]. The two compounds occupy completely different metabolic pathways. There is no competitive inhibition, enzyme induction, or transporter interference.

Pharmacodynamic Analysis

Rosuvastatin acts on hepatic cholesterol synthesis. Creatine acts on the phosphocreatine energy system in skeletal muscle. These mechanisms do not overlap. The American College of Cardiology and the American Heart Association's 2018 cholesterol management guidelines do not list creatine as a substance that interferes with statin therapy [8].

The Only Shared Concern: CK Elevation

Both rosuvastatin and creatine can independently raise creatine kinase (CK), though through different mechanisms. Statins can cause myopathy with CK elevations exceeding 10 times the upper limit of normal in approximately 0.1-0.2% of patients [9]. Creatine supplementation combined with resistance training commonly produces CK elevations of 200-500 IU/L that are exercise-related and benign [10]. If a patient taking both presents with muscle pain and elevated CK, the diagnostic workup becomes more complex because the clinician must distinguish statin-induced myotoxicity from exercise-induced CK release amplified by creatine supplementation.

Monitoring Strategy for Patients Taking Both

The practical management of this combination comes down to lab awareness and communication.

Step 1: Inform Your Prescriber

Dr. Jose Antonio, Professor at Nova Southeastern University and co-founder of the International Society of Sports Nutrition, has stated: "The single most important thing a creatine user can do before any medical lab work is tell their physician they are supplementing. Without that context, creatinine values become uninterpretable" [3].

Step 2: Consider Cystatin C

Cystatin C is an alternative biomarker for kidney function that is not affected by creatine supplementation, muscle mass, diet, or exercise. The Kidney Disease Improving Global Outcomes (KDIGO) 2024 guidelines recommend using cystatin C-based eGFR (eGFR-cys) or a combined creatinine-cystatin C equation (eGFR-cr-cys) when creatinine-based estimates may be inaccurate [11]. For statin patients taking creatine, requesting a cystatin C panel at baseline and annually eliminates the diagnostic confusion entirely.

Step 3: Washout Before Labs (Optional)

If cystatin C testing is unavailable or not covered by insurance, stopping creatine supplementation 3-5 days before a scheduled blood draw allows creatinine levels to return close to baseline. Creatine has a plasma half-life of approximately 3 hours, and complete washout of the creatinine elevation effect takes 4-7 days depending on the prior loading state [2].

Step 4: Baseline CK Level

Dr. Paul Thompson, former Chief of Cardiology at Hartford Hospital, has recommended: "Obtaining a pre-treatment CK level before starting a statin is particularly useful in patients who exercise intensely or take creatine, because it establishes a personal reference point for future myopathy evaluations" [9].

Request a CK measurement before initiating rosuvastatin therapy if you are already supplementing with creatine. This baseline becomes the benchmark for distinguishing exercise-related elevations from statin myotoxicity.

Dose Considerations

There is no pharmacological basis for adjusting the dose of either rosuvastatin or creatine when using them together.

Rosuvastatin Dosing

Standard rosuvastatin doses range from 5 mg to 40 mg daily. The JUPITER trial used 20 mg and demonstrated a 44% reduction in the primary cardiovascular endpoint [5]. Most patients achieve target LDL-C at 10-20 mg. The 40 mg dose, which carries the greatest renal monitoring burden, is reserved for patients who do not reach goal on lower doses.

Creatine Dosing

The International Society of Sports Nutrition's 2017 position stand recommends 3-5 g/day of creatine monohydrate for maintenance after an optional loading phase [12]. Doses at or below 5 g/day produce modest creatinine elevations that are less likely to confuse clinical interpretation compared with higher loading protocols.

Do You Need Dose Separation?

No. Because there is no pharmacokinetic interaction, taking rosuvastatin and creatine at the same time of day does not alter the absorption, distribution, metabolism, or excretion of either compound. Rosuvastatin can be taken at any time of day regardless of meals [1]. Creatine is typically taken with a post-workout meal or at a consistent daily time. There is no clinical reason to separate them by hours.

Populations That Need Extra Caution

Adults Over 65

Older adults have lower baseline GFR values and less muscle mass, which already complicates creatinine-based kidney estimates. Adding creatine supplementation to rosuvastatin therapy in this population makes cystatin C monitoring even more important. The 2018 ACC/AHA guidelines note that statin-associated muscle symptoms occur more frequently in older adults, and any additional CK confounder should be documented [8].

Patients with CKD Stage 3 or Higher

Patients with an eGFR of 30-59 mL/min/1.73 m² (CKD stage 3) can generally tolerate creatine at maintenance doses of 3-5 g/day based on available evidence, but the data in this population is limited [6]. Rosuvastatin dose should not exceed 10 mg in patients with severe renal impairment (eGFR <30) per FDA labeling [1]. These patients should use cystatin C rather than creatinine for all renal monitoring.

Patients on Combination Lipid Therapy

Rosuvastatin combined with fenofibrate or ezetimibe carries additive risks for CK elevation and myopathy. Adding creatine to a multi-drug lipid regimen increases the number of potential CK confounders. Patients on combination therapy should ensure their clinician has a complete supplement list before interpreting any muscle enzyme results.

What to Do If You Are Already Taking Both

If you are currently taking rosuvastatin and creatine without any adverse effects, there is no medical reason to stop either one. The following checklist keeps the combination safe long-term.

Confirm your prescriber knows you take creatine. Check that your most recent metabolic panel was interpreted with creatine use in mind. Request cystatin C at your next lab draw to get an unbiased GFR estimate. Keep your creatine dose at 3-5 g/day maintenance. Report any unexplained muscle pain, dark urine, or unusual fatigue to your clinician immediately, as these could signal rhabdomyolysis regardless of creatine status.

If a lab result shows rising creatinine, do not stop rosuvastatin on your own. A 2020 observational study in JAMA Cardiology found that statin discontinuation after a perceived adverse event was associated with a 13% increase in major cardiovascular events over 4 years [13]. The appropriate response is retesting with cystatin C or after a creatine washout period, not medication cessation.

The Bottom Line on Safety

The combination of rosuvastatin and creatine is not a pharmacological interaction. It is a diagnostic interpretation challenge. Creatine raises creatinine. Rosuvastatin requires creatinine monitoring. When the clinician is unaware of the supplement, the lab results tell a misleading story. Disclosure, cystatin C testing, and a baseline CK level before starting statin therapy eliminate the risk of misdiagnosis. Patients who maintain open communication with their prescriber can safely use both.

The ISSN's 2017 position stand concluded that creatine monohydrate has an "outstanding safety profile" at recommended doses [12]. Rosuvastatin at 5-20 mg daily has a well-documented cardiovascular benefit established across multiple large trials. There is no evidence-based reason to choose between the two.